Key facts
- Notable investors include Catalio Capital Management.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Rhapsogen
- ·The full record, as it builds
Funding rounds
No funding rounds for Rhapsogen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Rhapsogen
Developer of a novel class of biologic therapeutics designed to modulate antibody effector function to treat autoantibody-driven autoimmune diseases while preserving protective immune responses. The company offers antibody effector function rather than depleting B cells, enabling clients to get an effective reduction of tissue damage and inflammation in autoimmune diseases while maintaining immunity and offering potentially safer and durable care.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2025
- Employees
- 3
- Website
- rhapsogen.com/
- Ownership
- Privately Held (backing)
Rhapsogen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Rhapsogen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Rhapsogen in its N-PORT filings yet. We sweep new filings monthly.